Floatz logo

ly03010

Schizo Affective Disorder

Luye Pharma Group Ltd.Phase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

31 Active assets in the Schizo Affective Disorder cohort.

Asset / SponsorPhaseRating
Paliperidone Palmitate 3-Month Formulation
Luye Pharma Group Ltd.
Phase 4BBB
Seroquel®
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 4BBB
Lurasidone
University of Texas Southwestern Medical Center
Phase 4BBB
Bxcl501
BioXcel Therapeutics Inc
Phase 4BBB
Olanzapine
The Royal Ottawa Mental Health Centre
Phase 4BBB

View all 50 →

Same molecule, other indications

ly03010 is also rated in:

Antipsychotic AgentsDormant
CCC
Indicative ·
52 / 100
View asset →
mood disorderDormant
CCC
Indicative ·
52 / 100
View asset →
Physiological Effects of DrugsDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →